{
  "id": 13862843,
  "title": "Top stocks to buy: Stock recommendations for today",
  "url": "https://urgent.news/2026/10/12/top-stocks-to-buy-stock-recommendations-for-today",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-12T03:16:00.000Z",
  "source": {
    "name": "Times of India",
    "slug": "times-of-india",
    "url": "https://timesofindia.indiatimes.com/business/india-business/top-stock-recommendations-for-october-12-2026-week-bajaj-finance-molbio-diagnostics-stocks-to-buy-today/articleshow/134872816.cms"
  },
  "original_language": "en",
  "account": "The Motilal Oswal Wealth Management Research Desk has selected Bajaj Finance and Molbio Diagnostics as the top stocks to buy for the week of October 12, 2026. Bajaj Finance plans to raise up to Rs 17,500 crore through a fund raise that includes Rs 11,700 crore via QIP and Rs 5,800 crore through preferential warrants. This additional capital will bolster its balance sheet and support ongoing growth. The company experienced robust growth in Q2FY27, with its customer franchise expanding by 16.5% year-over-year to 128.9 million, assets under management increasing by 26.5% year-over-year to Rs 5.85 lakh crore, and its new loans book growing by 11% year-over-year despite the impact of the festive season on new loan bookings. Analysts anticipate continued earnings growth, estimating a compound annual growth rate (CAGR) of around 20% over the next two years, driven by sustained loan growth, an expanding customer base, and the benefits of scale.\n\nMolbio Diagnostics' growth is primarily fueled by its Truenat platform, a portable, battery-operated molecular testing solution with a quick turnaround time of around 60 minutes and minimal infrastructure requirements. The company boasts an extensive installed base of over 12,500 Truenat devices across 90+ countries and a diverse assay menu covering 30 diseases. This wide reach and expanding product portfolio position Molbio well for decentralized point-of-care diagnostics. With an estimated revenue CAGR of 23% and patent (PAT) CAGR of 50% over the 2026-2029 period, the company is poised for growth. This growth forecast is supported by factors such as higher test-kit sales, diversification into new areas, and operating leverage.",
  "summary": "Stock market recommendations: Bajaj Finance, Molbio Diagnostics - these are the top stocks to buy that Motilal Oswal Wealth Management Research Desk has picked for the week starting October 12, 2026.",
  "key_points": [
    "Bajaj Finance to raise Rs 17,500 crore through fund raise",
    "Molbio Diagnostics benefits from Truenat platform growth",
    "Molbio's revenue and patent growth CAGRs estimated at 23% and 50%"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}